PFIZER INC.

The global mRNA vaccine market is projected to decline at a CAGR of -4.3% from 2024 to 2034, reaching US$ 9.6 billion by 2034. Factors driving market growth include streamlined approval processes, innovations in logistics, increasing public trust, and ongoing research into long-term efficacy. Key players include Pfizer-BioNTech, Moderna, and Novartis, with North America leading in market share.

New COVID-19 boosters targeting recent strains like KP.2 were approved, aiming to enhance protection as fall approaches. Despite delays in vaccine shipments to some pharmacies, experts urge getting the booster and flu vaccine by October. High-risk individuals are especially encouraged to vaccinate early, with strategies like mask-wearing recommended for those awaiting vaccination.

Adding novel agents to perioperative durvalumab for NSCLC led to higher pCR and mPR rates compared to historical rates with durvalumab and chemotherapy. The highest response rates occurred with the addition of Dato-DXd (pCR 34.1%, mPR 65.9%). All combinations demonstrated manageable safety profiles and surgical rates comparable to approved regimens.

The European Commission approved BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation, based on the Phase II PHAROS trial results showing a 75% objective response rate (ORR) in treatment-naïve patients and 46% in previously treated patients. The approval addresses limited targeted treatment options for BRAFV600E mutant NSCLC patients.

Dupixent's dominance in the atopic dermatitis market is waning due to new treatments like Adbry, Cibinqo, and Rinvoq. Dermatologists estimate advanced systemic treatments now serve two-fifths of adult AD patients, highlighting the need for new options. Efficacy attributes like itch reduction and mechanism of action are key differentiators, with nemolizumab and lebrikizumab expected to further shift preferences away from Dupixent.

Dupixent's dominance in atopic dermatitis treatment is diminishing with the rise of competitors like Adbry, Cibinqo, and Rinvoq. Dermatologists anticipate adopting nemolizumab and lebrikizumab, further challenging Dupixent's market share.

The early development of GLP-1 drugs, led by Jeffrey Flier and colleagues, faced abandonment by Pfizer in 1991 due to misconceptions about their potential. Despite promising results, Pfizer's decision to focus on non-injection delivery methods led to the termination of the project. The GLP-1 class eventually achieved significant commercial success, highlighting the complexities and uncertainties in drug development.

GT Newsletter summarizes U.S. class-action decisions, including Supreme Court rulings on FAA exemptions and arbitration agreements, circuit court rejections of class certification, and district court analyses of ascertainability and predominance requirements.

A systematic review of real-world studies on advanced therapies for moderate-to-severe ulcerative colitis found Entyvio and Xeljanz most commonly studied, with Xeljanz showing higher remission rates. Entyvio outperformed TNF inhibitors in remission rates, while Remicade was most effective among TNF inhibitors. Safety profiles were similar across all therapies, though study limitations warrant further research.